The ongoing severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) pandemic has been a formidable global challenge. As yet, there are
very few drugs to treat this infection and no vaccine is currently available.
It has gradually become apparant that coronavirus disease 2019 (COVID-19) is
not a simple disease involving a single organ; rather, many vital organs and
systems are affected. 1. Established based on coronavirus control method,
constructed the carbon nanotube thermal conversion effect and nonspecific
antigen presentation nano light vaccine, can be used in a short time of carbon
nanotube heat resonance make the virus infection local rapid warming to 57
degrees Celsius, efficient kill virus, at the same time using nanotube carrier
of SARS-CoV-2 specific RBD combined with virus S protein, competitive
inhibition virus and the host cell membrane ACE 2 receptor, reduce the
infection rate, activate the body's T cell immunity, stimulate the
corresponding antibodies, to neutralize the invading virus immune response. At
the same time, the concentration control of nanomaterials can effectively
prevent the immune storm caused by the excessive activation of T cells and
reduce the immune damage. 2. It demonstrated the importance of the endothelial
system as an defense against viral infection, and maintaining the integrity of
endothelial morphology is an important measure to inhibit the host of viral
infection. 3. It is demonstrated that phospholipid S1P inside and outside the
cell membrane can effectively maintain cell membrane homeostasis, repair the
damaged cell membrane in time, and moderate S1P concentration is an important
method to protect the damage of the endothelial system, so as to effectively
inhibit SARS-CoV-2 infection.4 It discusses that the combination of
non-homologous multiple convalescent plasma-derived mAbs is an effective way to
solve the low efficiency of antibody neutralization and the limitation of
antibody specificity.
Author(s) Details:
Jianshe Yang,
Shanghai Tenth People’s Hospital of Tongji
University School of Medicine, Gansu Medical College, China.
Zhongwei
Lv,
Shanghai Tenth People’s Hospital of Tongji
University School of Medicine, China.
Qiang Wang,
Gansu Medical College, China.
Rongzhi Zhang,
Lanzhou University Second Hospital,
China.
Chengyou Jia,
State Grid Gansu Power Transmission and Transformation Engineering Company,
China.
Xiaoying
Zhang,
Shanghai Tenth People’s Hospital of Tongji
University School of Medicine, China.
Dan
Li,
Sun Yat-sen Hospital of Sun Yat-sen University,
China.
Siyang Zhou,
Gansu Medical College, China.
Fenfen Zhang,
Gansu Medical College, China.
Xuchang Zhang,
Second Affiliated Hospital of the Chinese University of Hong Kong, China.
Xinhuang Yao,
Second Affiliated Hospital of the
Chinese University of Hong Kong, China.
Shixin Lei,
Gansu Medical College, China.
Jinyu Tian,
Gansu Medical College, China.
Please see the link here: https://stm.bookpi.org/DTACSC/article/view/9548